DoD Traumatic Brain Injury and Psychological Health, Patient-Centered Research Award | W81XWH 22 TBIPHRP PCRA

Opportunity Information: Apply for W81XWH 22 TBIPHRP PCRA

The DoD Traumatic Brain Injury and Psychological Health, Patient-Centered Research Award (FY22 TBIPHRP PCRA; Funding Opportunity Number W81XWH-22-TBIPHRP-PCRA) is a Department of Defense funding opportunity designed to push proven or promising TBI and psychological health advances closer to real-world use. The central goal is to narrow the long-standing gap between what research shows can work and what actually gets adopted in clinics, health systems, and communities. Rather than focusing on early-stage discovery, this award emphasizes practical, patient-centered evidence about how to deploy interventions, clinical practices and guidelines, tools, and even policies so they reach the right populations at the right time and place, and lead to measurable patient benefit.

A defining feature of this program is its focus on implementation and real-world effectiveness. The DoD is looking for studies that build a knowledge base on dissemination, implementation, scale-up, sustainability, and appropriate use (or discontinuation) of clinical approaches relevant to TBI and psychological health. The opportunity supports clinical research and clinical trials only, meaning the work must be grounded in human-focused research. Preclinical studies and animal research are not allowed under this mechanism. Applicants may propose prospective or retrospective studies that involve human participants, human data or records, and/or human anatomical substances, but the program explicitly does not allow studies that require an Exception From Informed Consent (EFIC), which typically applies in certain emergency research situations.

The kinds of projects that fit this award are broad but clearly oriented toward patient-relevant outcomes and real-world decision-making. Competitive proposals may include comparative effectiveness research that weighs the benefits and harms of emerging or established interventions in routine care settings, where real patients and real constraints affect results. The award also supports development and testing of strategies to overcome barriers that keep evidence-based tools, policies, and guidelines from being adopted, adapted appropriately, integrated into workflows, expanded to larger populations, or sustained over time. In addition, applicants can analyze existing datasets or resources to inform clinical practice, refine or modify established clinical tools so they better fit the intended population or care environment, or evaluate existing tools with an eye toward improving outcomes that matter to patients. Notably, the scope also includes "de-implementation" research, meaning studies that identify when and why it is appropriate to stop or reduce the use of interventions, tools, or guidelines that are ineffective, unproven, low-value, or potentially harmful.

Several requirements shape how applicants must design their studies. The program mandates the use of Community-Based Participatory Research (CBPR) approaches in both development and execution of the proposed clinical research or trial, reinforcing that affected communities and stakeholders should meaningfully help shape the research questions, methods, and conduct of the work. These CBPR elements must be documented in specific application attachments (Attachments 11 and 12). Applicants must also include preliminary data that directly supports the feasibility or rationale of the proposed clinical research or trial. Where relevant, proposals should clearly demonstrate access to an appropriate patient population large enough to produce meaningful results, and if the project is a clinical trial, the trial is expected to begin within six months of the award date. If the study depends on a drug, device, compound, or other materials, the application is expected to show documented availability and access to those resources for the full proposed study period.

There are also compliance and transparency expectations for funded work. Trials supported by this award must post the IRB-approved informed consent form used for enrollment on a publicly available federal website, consistent with federal human subjects protection requirements described in 32 CFR 219. This aligns with broader federal expectations around ethical conduct, documentation, and public accountability in human subjects research.

From an administrative standpoint, this is a discretionary DoD opportunity under the U.S. Army Medical Research Acquisition Activity (USAMRAA), within the Congressionally Directed Medical Research Programs (CDMRP) ecosystem. It can be awarded as a grant or cooperative agreement, is categorized under science and technology and other research and development, and is listed under CFDA 12.420. Eligibility is described as unrestricted, meaning it is broadly open to different types of entities unless additional eligibility clarifications apply elsewhere in the full announcement. The FY22 posting listed an expected number of awards of 15, with an original application closing date of September 14, 2022. The listed award ceiling was shown as 0 in the extracted record, which typically means applicants need to consult the full announcement for specific budget limits or that ceilings may be handled in program-specific guidance rather than in that summary field.

Overall, this award is geared toward teams that already have a solid footing in clinical or clinical trial work and want to answer the next set of hard questions: how to make evidence-based TBI and psychological health approaches work in everyday settings, how to ensure they reach the people who need them, how to sustain them once implemented, and when it is appropriate to pull back from practices that do not deliver value or may cause harm.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Traumatic Brain Injury and Psychological Health, Patient-Centered Research Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Jul 15, 2022.
• Applicants must submit their applications by Sep 14, 2022. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 15 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 22 TBIPHRP PCRA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: